High Expression of VSTM2L Induced Resistance to Chemoradiotherapy in Rectal Cancer through Downstream IL-4 Signaling

Table 2

Correlation between clinical characteristics and expression of VSTM2L in GSE87211 about preoperative chemoradiotherapy of rectal cancer (total ).

Characteristics		VSTM2L expression (%)		value
		High ()	Low ()
Age	>60	40	74	0.144
	<60	33	39
Gender	Male	50	79	0.838
	Female	23	34
Kras mutation	Wild type	44	61	0.398
	Mutation type	29	52
Preoperative treatment	5-FU+RT	38	61	0.233
	5-FU+oxaliplatin+RT	35	48
	FU+oxaliplatin+cetuximab+RT	0	4
Invasion depth before pCRT	T2	1	4	0.166
	T3	65	105
	T4	7	4
Invasion depth after pCRT	T0	10	22	0.842
	T1	7	13
	T2	18	24
	T3	34	48
	T4	4	6
LN metastasis before pCRT	N0	29	33	0.137
	N1	44	80
LN metastasis after pCRT	N0	47	86	0.217
	N1	20	20
	N2	6	7
Metastasis before pCRT	M0	68	108	0.474
	M1	5	5
Metastasis after pCRT	M0	66	107	0.264
	M1	7	6
ypTNM stage before pCRT	I+II	29	31	0.080
	III+IV	44	82
TNM stage after pCRT	I+II	46	82	0.170
	III+IV	27	31
Tumor downstage after pCRT	No	33	37	0.087
	Yes	40	76
Tumor regression after pCRT	No	32	32	0.030
	Yes	41	81
Recurrence after surgery	No	51	89	0.170
	Yes	22	24

was considered significant.